Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-National, Multi-Centre, Open-Labelled Extension Study Assessing the Long-Term Safety of Biphasic Insulin Aspart 30 in NovoMix®30 FlexPen™ in Type 2 Diabetic Patients Previously Treated in BIAsp-1236

NCT01704378 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01704378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01704378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-National, Multi-Centre, Open-Labelled Extension Study Assessing the Long-Term Safety of Biphasic Insulin Aspart 30 in NovoMix®30 FlexPen™ in Type 2 Diabetic Patients Previously Treated in BIAsp-1236
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
April 18, 2001
Completion date
March 14, 2003
Enrollment
89 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2